Actively Targeted Low-Dose Camptothecin as a Safe, Long-Acting, Disease-Modifying Nanomedicine for Rheumatoid Arthritis

Author： Koo Otilia   Rubinstein Israel   Önyüksel Hayat  

Publisher： Springer Publishing Company

ISSN： 0724-8741

Source： Pharmaceutical Research, Vol.28, Iss.4, 2011-04, pp. : 776-787

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine

By Umićević Mirkov Maša   Coenen Marieke JH  

Pharmacogenomics, Vol. 14, Iss. 4, 2013-03 ,pp. : 425-444

Future Medicine

Access to resources Recommend Favorite

Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis

By Fleischmann Roy  

Expert Opinion on Drug Safety, Vol. 2, Iss. 4, 2003-07 ,pp. : 347-365

Informa Healthcare

Access to resources Recommend Favorite

Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis

By Nurmohamed Michael T.   Dijkmans Ben A.C.  

Drugs, Vol. 65, Iss. 5, 2005-01 ,pp. : 661-694

Adis International

Access to resources Recommend Favorite

Guidelines for the Use of Conventional and Newer Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis

By Díaz-Borjón Alejandro  

Drugs & Aging, Vol. 26, Iss. 4, 2009-05 ,pp. : 273-293

Adis International

Access to resources Recommend Favorite

The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs

By Drozdzik Marek   Rudas Tomasz   Pawlik Andrzej   Kurzawski Mateusz   Czerny Bogusław   Gornik Wanda   Herczynska Magdalena  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 11, 2006-11 ,pp. : 933-937

Springer Publishing Company

Access to resources Recommend Favorite